Leo Plouffe Jr
Overview
Explore the profile of Leo Plouffe Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stovall D, Utian W, Gass M, Qu Y, Muram D, Wong M, et al.
Menopause
. 2007 Feb;
14(3 Pt 1):510-7.
PMID: 17314736
Objective: To compare effects of 52 weeks' treatment with either raloxifene 60 mg/day alone (RLX) or in combination with 17beta-estradiol 1 mg/day (RLX + E) on vasomotor symptoms (n =...
2.
Recker R, Kendler D, Recknor C, Rooney T, Lewiecki E, Utian W, et al.
Bone
. 2006 Dec;
40(4):843-51.
PMID: 17182297
Unlabelled: The double-blind, randomized raloxifene alendronate comparison trial was the first study designed to compare two osteoporosis therapies head-to-head for fracture risk reduction. The original protocol planned to treat 3000...
3.
Weinstein D, Cohen J, Liu C, Meadows E, Plouffe Jr L, Muram D
Curr Med Res Opin
. 2006 Nov;
22(11):2121-9.
PMID: 17076972
Objective: To evaluate the effectiveness and safety of duloxetine for the treatment of African-American and Hispanic women with stress urinary incontinence. Research Design And Methods: The 10-week (a 2-week lead...
4.
Draper M, Plouffe Jr L
Obstet Gynecol
. 2005 Nov;
106(5 Pt 1):1110-1.
PMID: 16260540
No abstract available.
5.
Hansen K, Zhang Y, Colver R, Tho S, Plouffe Jr L, McDonough P
Fertil Steril
. 2005 Sep;
84(3):711-8.
PMID: 16169407
Objective: To evaluate patients with hyperprolactinemia for the presence of dopamine receptor D2 polymorphisms. Design: Case-control study. Setting: Academic research environment. Patient(s): Women and men with pathologic hyperprolactinemia and healthy...
6.
Kulkarni P, Meadows E, Ahuja S, Muram D, Plouffe Jr L
Curr Med Res Opin
. 2004 Oct;
20(10):1641-7.
PMID: 15462697
Although double-blind, placebo-controlled clinical trials are utilized extensively to characterize the efficacy and safety of new treatment options, the characteristics of the trial participants often do not reflect those of...
7.
Grady D, Ettinger B, Moscarelli E, Plouffe Jr L, Sarkar S, Ciaccia A, et al.
Obstet Gynecol
. 2004 Oct;
104(4):837-44.
PMID: 15458908
Objective: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen. Methods: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind...
8.
Silverman S, Delmas P, Kulkarni P, Stock J, Wong M, Plouffe Jr L
J Am Geriatr Soc
. 2004 Sep;
52(9):1543-8.
PMID: 15341559
Objectives: To compare event rates for osteoporotic fractures, cardiovascular events, and breast cancer in postmenopausal women with osteoporosis. Design: A prospective, observational study of the placebo group in the double-blind,...
9.
Lufkin E, Sarkar S, Kulkarni P, Ciaccia A, Siddhanti S, Stock J, et al.
Curr Med Res Opin
. 2004 Mar;
20(3):351-7.
PMID: 15025844
Standard pharmacological antiresorptive therapy for the prevention and/or treatment of postmenopausal osteoporosis now consists of four categories of drugs: estrogens, a selective estrogen receptor modulator (SERM), bisphosponates, and calcitonin. All...
10.
Gordon S, Walsh B, Ciaccia A, Siddhanti S, Rosen A, Plouffe Jr L
Obstet Gynecol
. 2004 Feb;
103(2):267-73.
PMID: 14754694
Objective: To compare vasomotor symptoms after transition from estrogen-progestin therapy to raloxifene 60 mg/d with and without a placebo washout. Methods: Postmenopausal women currently taking continuous combined estrogen-progestin therapy (conjugated...